Selected Platelet Aggregation Inhibitors/NSAIDs Interactions

This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.

Medical warning:

Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.

How the interaction occurs:

Platelet aggregation inhibitors and NSAIDs decrease your body's ability to make clots.

What might happen:

You may experience an increased chance for bleeding including bleeding from your gums, nosebleeds, unusual bruising, or dark stools.

What you should do about this interaction:

Let your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these two medicines together. They may already may be aware of this interaction and may be monitoring you for it. If your doctor prescribes these medicines together, you may need to check your bleeding times more often. Do not start, stop, or change the dosage of any medicine before checking with them first. Let your doctor know right away if you have any symptoms of bleeding.

  • 1.ReoPro (abciximab) US prescribing information. Eli Lilly and Company November 25, 2013.
  • 2.Integrilin (eptifibatide) US prescribing information. Schering Corporation March, 2011.
  • 3.Plavix (clopidogrel hydrogen sulfate) Australian prescribing information. Sanofi-Synthelabo Australia Pty Limited September 22, 2004.
  • 4.Plavix (clopidogrel hydrogen sulphate) UK summary of product characteristics. Sanofi Pharma Bristol-Myers Squibb SNC February 22, 2005.
  • 5.Plavix (clopidogrel bisulfate) US prescribing information. Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership July 10, 2017.
  • 6.Abraham NS, et al. ACCF-ACG-AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors & thienopyridines: a focused update of the ACCF-ACG-AHA 2008 expert consensus document. Circulation 2010 Dec 14;122(24):2619-33.